This database contains 524 studies, archived under the term: "alzheimer disease"
Click here to filter this large number of results.
Diagnostic and economic evaluation of new biomarkers for Alzheimer’s disease: the research protocol of a prospective cohort study
Handels, Ron L.H.,
Aalten, Pauline,
Wolfs, Claire A.G.,
OldeRikkert, Marcel,
Scheltens, Philip,
Visser, Pieter Jelle,
Joore, Manuela A.,
Severens, Johan L.,
Verhey, Frans R.J.
Background: New research criteria for the diagnosis of Alzheimer’s disease (AD) have recently been developed to enable an early diagnosis of AD pathophysiology by relying on emerging biomarkers. To enable efficient allocation of health care resources, evidence is needed to support decision makers on the adoption of emerging biomarkers in clinical practice. The research goals […]
Relapse risk after discontinuation of risperidone in Alzheimer’s disease
Devanand, D. P.,
Mintzer, Jacobo,
Schultz, Susan K.,
Andrews, Howard F.,
Sultzer, David L.,
de la Pena, Danilo,
Gupta, Sanjay,
Colon, Sylvia,
Schimming, Corbett,
Pelton, Gregory H.,
Levin, Bruce
Background: Among patients with Alzheimer’s disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation of the medication has not been established.; Methods: Patients with Alzheimer’s disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks. Those who had a […]
The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design
Devanand, D. P.,
Mintzer, Jacobo,
Schultz, Susan,
Sultzer, David,
de la Pena, Danilo,
Gupta, Sanjay,
Colon, Sylvia,
Schimming, Corbett,
Pelton, Gregory H.,
Andrews, Howard,
Levin, Bruce
Objectives: : Research studies on the effects of discontinuing antipsychotic medications in patients with dementia have not identified specific target symptoms or response to antipsychotics prior to discontinuation. The Antipsychotic Discontinuation in Alzheimer Disease (ADAD) trial addresses these issues in a randomized, double-blind, placebo-controlled, multicenter risperidone treatment and discontinuation trial. In Phase A, AD patients […]
Alzheimer’s disease multiple intervention trial (ADMIT): study protocol for a randomized controlled clinical trial
Callahan, Christopher M.,
Boustani, Malaz A.,
Schmid, Arlene A.,
Austrom, Mary G.,
Miller, Douglas K.,
Gao, Sujuan,
Morris, Carrie S.,
Vogel, Mickey,
Hendrie, Hugh C.
Background: Given the current lack of disease-modifying therapies, it is important to explore new models of longitudinal care for older adults with dementia that focus on improving quality of life and delaying functional decline. In a previous clinical trial, we demonstrated that collaborative care for Alzheimer’s disease reduces patients’ neuropsychiatric symptoms as well as caregiver […]
Effectivity of early psychosocial counselling for family caregivers in general practioner based dementia care
Geschke, K.,
Scheurich, A.,
Schermuly, I.,
Laux, N.,
Böttcher, A.,
Fellgiebel, A.
Background: Psychoeducation and professional support of family caregivers are regarded as important aspects in dementia care. In the context of a general practitioner’s (GP) based dementia care project we investigated if professional counselling after making a diagnosis of dementia can reduce the development of depression in family caregivers.; Methods: 42 patients with dementia and their […]
Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease – protocol for a controlled, randomized double-blinded trial
Egefjord, Lærke,
Gejl, Michael,
Møller, Arne,
Brændgaard, Hans,
Gottrup, Hanne,
Antropova, Olga,
Møller, Niels,
Poulsen, Henrik E.,
Gjedde, Albert,
Brock, Birgitte,
Rungby, Jørgen
Introduction: Type 2 diabetes (DM-2) increases the risk of developing Alzheimer´s disease (AD), and patients with AD are more likely to develop DM-2. DM-2 and AD share some pathophysiological features. In AD, amyloid-β (Aβ) is accumulated as extracellular plaques in the gray matter of the brain, while in DM-2 islet amyloid polypeptide (IAPP) is accumulated […]